MedTrace Logo

Efficacy and Safety of Lu AA34893 in Patients With Major Depressive Disorder

NCT00766870 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2010-09-29

No results posted yet for this study

Summary

The purpose of the study is to evaluate the efficacy, safety and tolerability of three fixed dosages of Lu AA34893 compared to placebo in the treatment of patients with Major Depressive Disorder.

Conditions

Interventions

DRUG

Lu AA34893

Per oral doses, divided in twice daily administrations as capsules during 8 weeks, followed by a two-week tapering period

DRUG

Venlafaxine extended release

Per oral, once daily, during 8 weeks, followed by a two-week tapering period

DRUG

Placebo

Per oral doses, twice daily as capsules during 10 weeks

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2009-01-31
Completion
2009-02-28

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00766870 on ClinicalTrials.gov